85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
Titel:
85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
Auteur:
Jie, W. Wu, Y-L. Lu, S. Wang, Q. Li, S. Zhong, W. Wang, Q. Li, W. Wang, B. Chen, J. Cheng, Y. Duan, H. Li, G. Shan, L. Liu, Y. Huang, X. Atasoy, A. He, J.